ES2306163T3 - Tratamiento de esteatohepatitis no alcoholica (nash). - Google Patents

Tratamiento de esteatohepatitis no alcoholica (nash). Download PDF

Info

Publication number
ES2306163T3
ES2306163T3 ES05753069T ES05753069T ES2306163T3 ES 2306163 T3 ES2306163 T3 ES 2306163T3 ES 05753069 T ES05753069 T ES 05753069T ES 05753069 T ES05753069 T ES 05753069T ES 2306163 T3 ES2306163 T3 ES 2306163T3
Authority
ES
Spain
Prior art keywords
lpl
therapeutic
use according
protein
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05753069T
Other languages
English (en)
Spanish (es)
Inventor
Sander Jan Hendrik Van Deventer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amsterdam Molecular Therapeutics AMT BV
Original Assignee
Amsterdam Molecular Therapeutics AMT BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amsterdam Molecular Therapeutics AMT BV filed Critical Amsterdam Molecular Therapeutics AMT BV
Application granted granted Critical
Publication of ES2306163T3 publication Critical patent/ES2306163T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES05753069T 2004-06-21 2005-06-20 Tratamiento de esteatohepatitis no alcoholica (nash). Expired - Lifetime ES2306163T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58090304P 2004-06-21 2004-06-21
US580903P 2004-06-21

Publications (1)

Publication Number Publication Date
ES2306163T3 true ES2306163T3 (es) 2008-11-01

Family

ID=34970452

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05753069T Expired - Lifetime ES2306163T3 (es) 2004-06-21 2005-06-20 Tratamiento de esteatohepatitis no alcoholica (nash).

Country Status (16)

Country Link
US (2) US20080280823A1 (enExample)
EP (1) EP1761273B1 (enExample)
JP (1) JP2008503569A (enExample)
KR (1) KR20070057712A (enExample)
CN (1) CN1972709A (enExample)
AT (1) ATE395073T1 (enExample)
AU (1) AU2005253897B2 (enExample)
CA (1) CA2568643A1 (enExample)
CY (1) CY1108552T1 (enExample)
DE (1) DE602005006809D1 (enExample)
DK (1) DK1761273T3 (enExample)
ES (1) ES2306163T3 (enExample)
PL (1) PL1761273T3 (enExample)
PT (1) PT1761273E (enExample)
SI (1) SI1761273T1 (enExample)
WO (1) WO2005123117A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
WO2010134806A1 (en) * 2009-05-18 2010-11-25 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Use of lipoprotein lipase (lpl) in therapy
CN102628060A (zh) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 一种低脂奶的生产方法
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
CN115109788A (zh) * 2021-03-23 2022-09-27 北京锦篮基因科技有限公司 Aav介导的人脂蛋白脂酶肝脏异位表达载体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5799200A (en) * 1999-06-24 2001-01-31 Academic Hospital At The University Of Amsterdam Lpl variant therapeutics
FR2795832B1 (fr) * 1999-06-30 2004-06-18 Plastic Omnium Valeo Interiors Dispositif de commande d'actionneur notamment pour vehicule
AU6814901A (en) * 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors

Also Published As

Publication number Publication date
AU2005253897A1 (en) 2005-12-29
CY1108552T1 (el) 2014-04-09
JP2008503569A (ja) 2008-02-07
AU2005253897B2 (en) 2011-09-01
CA2568643A1 (en) 2005-12-29
CN1972709A (zh) 2007-05-30
US20110081332A1 (en) 2011-04-07
EP1761273A1 (en) 2007-03-14
ATE395073T1 (de) 2008-05-15
KR20070057712A (ko) 2007-06-07
WO2005123117A1 (en) 2005-12-29
PL1761273T3 (pl) 2008-10-31
SI1761273T1 (sl) 2008-10-31
DK1761273T3 (da) 2008-08-04
DE602005006809D1 (de) 2008-06-26
US20080280823A1 (en) 2008-11-13
EP1761273B1 (en) 2008-05-14
PT1761273E (pt) 2008-10-28

Similar Documents

Publication Publication Date Title
ES2507540T3 (es) Terapia génica de porfobilinógeno deaminasa
JP2022525955A (ja) 組換えアデノ随伴ウイルスベクター
ES2311464T3 (es) Terapia con variante de lipoproteina lipasa (lpl).
AU2025206429A1 (en) Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2A
JP2015503924A (ja) 遺伝子導入のための方法及び組成物
AU770384B2 (en) Methods of altering cardiac cell phenotype
US20110081332A1 (en) Treatment of non-alcoholic steatotic hepatitis (nash)
Yadav et al. Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM
JP2021531044A (ja) ムコ多糖症ｉｖａ型の治療
JP2019070001A (ja) 肝細胞増殖因子及びストローマ細胞由来因子１αを用いた末梢動脈疾患の予防または治療用組成物
JPWO2020223362A5 (enExample)
Inui et al. Gene therapy in Duchenne muscular dystrophy
CN118416257A (zh) Mif基因在制备治疗和/或预防心肌缺血损伤的药物中的应用、载体和药物
TW202337476A (zh) 用於與肌肉萎縮蛋白有關之心肌病之基因療法組合物及治療
US20110301568A1 (en) Systems and Methods to Treat Cardiac Pacing Conditions
WO2015153357A1 (en) Compositions and methods for improving cardiac function
KR20210005612A (ko) 산화성 스트레스에 대한 유전자 요법